Brewin Dolphin Wealth Management’s NovoCure NVCR Stock Holding History

Brewin Dolphin Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$14K	Hold	200	–	–	﹤0.01%	270
2022 Q1	$17K	Hold	200	–	–	﹤0.01%	263
2021 Q4	$15K	Hold	200	–	–	﹤0.01%	276
2021 Q3	$23.2K	Hold	200	–	–	﹤0.01%	256
2021 Q2	$44.4K	Hold	200	–	–	0.01%	199
2021 Q1	$26.4K	Hold	200	–	–	﹤0.01%	233
2020 Q4	$34.6K	Buy	+200	New	+$27.4K	0.01%	190

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brewin Dolphin Wealth Management's NVCR Position: Q2 2022 in Review

Brewin Dolphin Wealth Management held its NovoCure (NVCR) position steady in Q2 2022 at 200 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #270.

Brewin Dolphin Wealth Management first reported a position in NVCR in Q4 2020 and has held it in 7 quarters since. The position peaked at $44.4K in Q2 2021. 316 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

Brewin Dolphin Wealth Management held 200 shares of NovoCure worth $14K as of Q2 2022.
Brewin Dolphin Wealth Management left its NovoCure share count unchanged in Q2 2022.
NovoCure made up ﹤0.01% of Brewin Dolphin Wealth Management's portfolio in Q2 2022, its #270 holding.
Brewin Dolphin Wealth Management first reported a position in NovoCure in Q4 2020 and has held it in 7 quarters since.
Brewin Dolphin Wealth Management's NovoCure position peaked at $44.4K in Q2 2021.
316 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on Brewin Dolphin Wealth Management's 13F filing for Q2 2022, filed 14 Nov 2022.